title: The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.
abstract: Epithelial ovarian cancer (EOC) is the sixth most common cause of cancer deaths in women because the diagnosis occurs mostly when the disease is in its late-stage. Current diagnostic methods of EOC show only a moderate sensitivity, especially at an early-stage of the disease; hence, novel biomarkers are needed to improve the diagnosis. We recently reported that serum glycome modifications observed in late-stage EOC patients by MALDI-TOF-MS could be combined as a glycan score named GLYCOV that was calculated from the relative areas of the 11 N-glycan structures that were significantly modulated. Here, we evaluated the ability of GLYCOV to recognize early-stage EOC in a cohort of 73 individuals comprised of 20 early-stage primary serous EOC, 20 benign ovarian diseases (BOD), and 33 age-matched healthy controls. GLYCOV was able to recognize stage I EOC whereas CA125 values were statistically significant only for stage II EOC patients. In addition, GLYCOV was more sensitive and specific compared to CA125 in distinguishing early-stage EOC from BOD patients, which is of high relevance to clinicians as it is difficult for them to diagnose malignancy prior to operation.
authors.affiliation: Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Karina
authors.identifier: 0000-0002-1558-7778
authors.initials: K
authors.lastname: Biskup
authors.affiliation: Department of Gynecology, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Elena Iona
authors.initials: EI
authors.lastname: Braicu
authors.affiliation: Department of Gynecology, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.affiliation: Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Tauber
authors.affiliation: Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: Véronique
authors.initials: V
authors.lastname: Blanchard
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis; D011134:Polysaccharides / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D011134:Polysaccharides